Spero Therapeutics Files 2024 10-K
Ticker: SPRO · Form: 10-K · Filed: Mar 27, 2025 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | 10-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, agreements
TL;DR
Spero's 2024 10-K is in, check out Pfizer & BARDA deals.
AI Summary
Spero Therapeutics, Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceutical preparations, is based in Cambridge, MA. Key agreements mentioned include those with Pfizer and the Biomedical Advanced Research and Development Authority (BARDA).
Why It Matters
This filing provides a comprehensive overview of Spero Therapeutics' financial health, business operations, and strategic direction for the fiscal year 2024, impacting investors and stakeholders.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Spero Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-27 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-27 (date) — Filing date
- Pfizer (company) — Party to license and share purchase agreements
- Biomedical Advanced Research and Development Authority (company) — Party to base period contracts
- Cambridge, MA (location) — Company headquarters
FAQ
What were the key financial highlights for Spero Therapeutics in fiscal year 2024?
The provided text does not contain specific financial figures for fiscal year 2024, but it indicates the filing date and fiscal year end.
What is the primary business of Spero Therapeutics?
Spero Therapeutics, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].
What significant agreements does Spero Therapeutics have?
Spero Therapeutics has entered into Pfizer License and Share Purchase Agreements and Base Period Contracts with the Biomedical Advanced Research and Development Authority (BARDA).
When was Spero Therapeutics, Inc. formerly known as Spero Therapeutics, LLC?
The company changed its name from Spero Therapeutics, LLC on March 16, 2017.
Where is Spero Therapeutics located?
Spero Therapeutics, Inc. is located at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 27, 2025 regarding Spero Therapeutics, Inc. (SPRO).